SICOR Announces ANDA Approval for Vincristine Sulfate

SICOR Inc. (Nasdaq: SCRI) today announced that its wholly owned subsidiary, Gensia Sicor Pharmaceuticals, Inc., has received approval of an Abbreviated New Drug Application (ANDA) from the Food and Drug Administration (FDA) for Vincristine Sulfate Injection USP, a drug indicated for acute leukemia. According to IMS, a market research firm, U.S. sales of Vincristine were approximately $5 million in 1998. The branded product, Oncovin(R) Injection, is marketed by Eli Lilly and Company. SICOR Inc. is a vertically integrated specialty pharmaceutical company with proven expertise in the development, manufacturing and marketing of multi-source injectable pharmaceuticals. With a strategy of combining both the production of active pharmaceutical ingredients utilizing synthesis or fermentation and state of the art manufacturing facilities, SICOR's primary focus is on the worldwide injectable pharmaceutical market, which currently includes oncology, anesthesiology, cardiology and other therapeutic areas. SICOR operates several manufacturing facilities in Europe, Mexico and the U.S.A., while maintaining its corporate headquarters in Irvine, California. This press release contains forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward looking statements and those matters set forth in the risk factors section of SICOR's filings on Forms 10-K and 10-Q with the Securities and Exchange Commission. These forward looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward looking statements. For more information on the Company, visit SICOR's web site at www.gensiasicor.com. News releases are also available at no charge through PR Newswire's News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by SICOR, call 800-758-5804, extension 354050. Please retain these numbers for future reference. ots Original Text Service: SICOR Inc. Internet: http://www.newsaktuell.de Contact: Laurie W. Little of SICOR Inc., (USA) 949-455-4879; or Carolyn Bass or Jim Byers, (USA) 415-296-7383, or Patricia Walsh or Eric Gonzales, (USA) 212-850-5600, all of Morgen-Walke Associates, Inc., for SICOR Inc. Company News On-Call: http://www.prnewswire.com/comp/354050.html or Fax, (USA) 800- 758-5804, ext. 354050 Web site: http://www.gensiasicor.com

Klíčová slova PROTEXT-SICOR Inc.

Oblast
USA, Kanada, OSN, svět a Arktida (us)

Kategorie
Zdravotnictví

ZASÍLÁNÍ ZPRÁV
Přihlásit k odběru

Upozornění:
Materiály označené značkou Protext nejsou součástí zpravodajského servisu ČTK a nelze je publikovat pod její značkou. Jde o komerční sdělení zadavatele, který je ve zprávě označen a který za ně nese plnou odpovědnost.